IBI-322
Product Specifications
Target
PD-1/PD-L1, Others
Related Pathways
Apoptosis, Others, Immunology/Inflammation, Cell Cycle/Checkpoint
Bioactivity
IBI-322 is a bispecific antibody targeting PD-L1 and CD47. In monovalent binding, it can attenuate the activity of CD47, and in bivalent binding, it can block the activity of PD-L1. IBI-322 selectively binds to CD47+PD-L1+ tumor cells, effectively inhibiting the CD47-SIRPα signaling and inducing strong tumor cell phagocytosis in vitro.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
